Purpose: People with type 2 diabetes mellitus (DM2) have an increased risk of Alzheimer’s Disease (AD). GLP1 receptor agonists (GLP1RAs) and SGLT2 inhibitors (SGLT2i) have emerged as potential interventions to prevent AD and dementia and may provide insights into disease mechanisms. Methods: PubMed, Embase, and Cochrane were searched for randomized controlled trials (RCTs), cohort, and case control studies between January 1, 2006, and April 15, 2025, comparing GLP1RAs and/or SGLT2i in adults with DM2 without cognitive impairment at baseline.
GLP-1 Receptor Agonists vs SGLT2 Inhibitors for Alzheimer Disease Risk in Type 2 Diabetes: A Systematic Review and Meta-Analysis
calendar_today
July 24, 2026
person
Silva, L. L., Valverde, M. S., Silva, A. M., Braz, L. D., da Silva, K. K., Aguiar, E. M., Volta, V. D., de Oliveira, C., Alves, R. R., Andreao, F. F., Moura, C. B., Santos, D. H.
domain
medrxiv